The document addresses data integrity issues within the pharmaceutical industry, emphasizing the importance of accurate and reliable data for producing safe medicines. It outlines the key attributes of data integrity and discusses the various challenges faced by Indian pharmaceutical companies, including multiple warning letters from the US FDA. The upcoming seminar, scheduled for July 28-29, 2017, in Mumbai, aims to provide solutions and best practices for addressing these challenges and improving compliance with regulatory standards.